Vyome Holdings, Inc cash flow statement
In fiscal 2025, Vyome Holdings, Inc's operations generated −$3.7m of cash; it spent $0 on capital projects, leaving free cash flow of −$3.7m.
Cash flow statement
| Fiscal year | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −10 | −11 | −19 | −31 | −29 | −23 | −9 | −15 | −22 | −17 | −1 | −4 | −6 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 0 | 0 | 1 | 3 | 5 | 3 | 1 | 12 | 2 | 1 | 0 | 1 | 1 |
| Capital spending | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −10 | −12 | −20 | −32 | −31 | −23 | −9 | −16 | −22 | −17 | −1 | −4 | −6 |
| Free cash flow after stock pay | −10 | −12 | −20 | −35 | −35 | −26 | −10 | −28 | −24 | −18 | −1 | −4 | −6 |
| Shares issued | — | — | — | 0 | 10 | 23 | 0 | — | 1 | 13 | — | 1 | −4 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 3 | −0 | −0 | −0 | −2 | −1 | −1 | −1 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 3 | −0 | −0 | −0 | −2 | −1 | −1 | −1 |
| Free cash flow after stock pay | 3 | −0 | −0 | −0 | −2 | −1 | −1 | −1 |
| Shares issued | — | — | 5 | 6 | −10 | 1 | 5 | −0 |
Compare with peers
- Akanda Corp. cash flow
- Scienture Holdings, Inc. cash flow
- PRF Technologies Ltd. cash flow
- 60 Degrees Pharmaceuticals, Inc. cash flow
- China SXT Pharmaceuticals, Inc. cash flow
Head to head: AKAN vs HINDHIND vs SCNXHIND vs PRFX
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies